Pelthos Therapeutics Inc.

For the period ended Sep 30, 2025. Filed Nov 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 13, 2025

PTHS$8.90-5.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

FOR THE****THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

	Preferred A Shares	Preferred A Shares Par	Preferred C Shares	Preferred C Shares Par	Common Shares	Par	Additional Paid-in Capital	Accumulated Deficit	Total Stockholders’ Equity (Deficit)
Balance, December 31, 2024	—	$—	2,600	$—	610,389	$—	$18,761	$(21,475)	$(2,714)
Stock-based compensation	—	—	—	—	—	—	404	—	404
Restricted stock unit expense	—	—	—	—	4,635	—	52	—	52
Shares issued for services	—	—	—	—	1,692	—	30	—	30
Shares issued for cash	—	—	—	—	1,650	—	—	—	—
Net loss	—	—	—	—	—	—	—	(1,968)	(1,968)
Balance, March 31, 2025	—	$—	2,600	$—	618,366	$—	$19,247	$(23,443)	$(4,196)
Stock-based compensation	—	—	—	—	—	—	342	—	342
Restricted stock unit expense	—	—	—	—	4,635	—	52	—	52
Shares issued for services	—	—	—	—	1,389	—	20	—	20
Shares issued for conversion of notes	—	—	—	—	48,938	—	737	—	737
Stock split	—	—	—	—	(8)	—	—	—	—
Net loss	—	—	—	—	—	—	—	(3,449)	(3,449)
Balance, June 30, 2025	—	$—	2,600	$—	673,320	$—	$20,398	$(26,892)	$(6,494)
Stock-based compensation	—	—	—	—	—	—	2,001	—	2,001
Restricted stock unit expense	—	—	—	—	22,155	—	811	—	811
Exercise of stock options	—	—	—	—	6,500	—	85	—	85
Stock split	—	—	—	—	7,754	—	—	—	—
Shares issued in Acquisition of LNHC, Inc.	31,278	—	—	—	—	—	39,410	—	39,410
Shares issued in PIPE Financing	50,100	—	—	—	—	—	38,678	—	38,678
Conversion of Preferred A Shares	(23,810)	—	—	—	2,381,000	—	—	—	—
Net loss	—	—	—	—	—	—	—	(16,238)	(16,238)
Balance, September 30, 2025	57,568	$—	2,600	$—	3,090,729	$—	$101,383	$(43,130)	$58,253

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

FOR THE****THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024 (CONTINUED)

	Preferred A Shares	Preferred A Shares Par	Preferred C Shares	Preferred C Shares Par	Common Shares	Par	Additional Paid-in Capital	Accumulated Deficit	Total Stockholders’ Equity (Deficit)
Balance, December 31, 2023	600,000	$—	—	$—	390,634	$—	$7,075	$(13,520)	$(6,445)
Stock-based compensation	—	—	—	—	—	—	293	—	293
Issuance cost from common stock issued for extension of bridge loan	—	—	—	—	8,112	—	448	—	448
Conversion of preferred stock	(600,000)	—	—	—	49,943	—	—	—	—
Common stock issued for cash	—	—	—	—	110,000	—	5,972	—	5,972
Standby agreement	—	—	—	—	3,750	—	—	—	—
Recission of common stock	—	—	—	—	(11,113)	—	(92)	—	(92)
Transfer of liabilities to Chromocell Corp. for preferred C shares	—	—	2,600	—	—	—	2,153	—	2,153
Common stock issued for conversion of notes	—	—	—	—	25,350	—	1,363	—	1,363
Net loss	—	—	—	—	—	—	—	(2,562)	(2,562)
Balance, March 31, 2024	—	$—	2,600	$—	576,676	$—	$17,212	$(16,082)	$1,130
Stock-based compensation	—	—	—	—	—	—	366	—	366
Restricted stock unit expense	—	—	—	—	—	—	14	—	14
Shares issued for services	—	—	—	—	5,647	—	78	—	78
Net loss	—	—	—	—	—	—	—	(1,772)	(1,772)
Balance, June 30, 2024	—	$—	2,600	$—	582,323	$—	$17,670	$(17,854)	$(184)
Stock-based compensation	—	—	—	—	—	—	395	—	395
Restricted stock unit expense	—	—	—	—	3,225	—	42	—	42
Shares issued for services	—	—	—	—	3,890	—	81	—	81
Shares issued for payment of accounts payable	—	—	—	—	1,000	—	7	—	7
Stock repurchase	—	—	—	—	(8,620)	—	(74)	—	(74)
Net loss	—	—	—	—	—	—	—	(1,695)	(1,695)
Balance, September 30, 2024	—	$—	2,600	$—	581,818	$—	$18,121	$(19,549)	$(1,428)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE**

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.